NCT07393321 2026-02-06
A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer
Nanjing Chia-tai Tianqing Pharmaceutical
Phase 3 Not yet recruiting
Clinical Trials
3 trialsNCT06929325 2025-04-16
Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Not yet recruiting
NCT04337658 2020-04-08
FAVOR
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Not yet recruiting